DXCM · DexCom, Inc.
$77.94
-0.48% last session
End-of-day data · close of 2026-10-23
Market cap
$29B
Enterprise value
$29B
Trailing P/E
30.9
Forward P/E
25.0
Dividend yield
0.0%
Beta
1.48
Avg volume
4M
Employees
11K
Daily Change %
-0.48%
5 Days Change
-8.97%
10 Days Change
-7.92%
30 Days Change
-10.73%
60 Days Change
-13.99%
Month to Day Change
-9.17%
Year to Day Change
18.01%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DXCM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
Barclays
Overweight$115
+47.5% vs priceRBC Capital
Outperform$105
+34.7% vs priceCitigroup
Buy$88.00
+12.9% vs priceJP Morgan
Neutral$82.00
+5.2% vs priceWells Fargo
Overweight$90.00
+15.5% vs priceDeutsche Bank
Buy$86.00
+10.3% vs priceBank of America
Buy$80.00
+2.6% vs priceMorgan Stanley
Overweight$75.00
-3.8% vs priceUBS
Buy$95.00
+21.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | BTIG | Maintains | Buy | $90.00 → $96.00 |
| 2026-10-07 | Barclays | Initiates | Overweight | $0.00 → $115 |
| 2026-10-01 | RBC Capital | Maintains | Outperform | $90.00 → $105 |
| 2026-09-18 | Truist Securities | Maintains | Buy | $93.00 → $102 |
| 2026-09-18 | TD Cowen | Reiterates | Buy | $95.00 |
| 2026-08-04 | Argus Research | Maintains | Buy | $86.00 → $96.00 |
| 2026-08-03 | Canaccord Genuity | Maintains | Buy | $82.00 → $90.00 |
| 2026-07-31 | Citigroup | Maintains | Buy | $84.00 → $88.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 32 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 10.2% below the 50-day MA ($86.83).
- bullish: Price vs 200-day MA: Trading 4.9% above the 200-day MA ($74.31).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.78) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($54.84) and high ($92.34).
DXCM Price Chart
Loading chart for DXCM…
Fundamentals
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
More in Medical Devices
ABT
Abbott Laboratories
$179B -16.2% YTD
MDT
Medtronic plc.
$122B 3.1% YTD
SYK
Stryker Corporation
$118B -11.9% YTD
BSX
Boston Scientific Corporation
$66B -51.7% YTD
EW
Edwards Lifesciences Corporatio
$51B 5.7% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.8% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 3.3% YTD
STE
STERIS plc (Ireland)
$23B -7.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.